#ajan reginald stem cells

[ajanreginalduk-blog]

Ajan Reginald, CEO of Celixir (formerly Cell Therapy Limited) - An Entrepreneur based in London, UK

Ajan Reginald, CEO of Celixir (formerly Cell Therapy Limited) is an entrepreneur based in London, UK.  Ajan Reginald is a graduate in dental surgery and masters in Biotechnology with a combinational background in science and business. A vivid hockey player, Ajan has played at international levels and is actively involved in the work of Hockey.

Ajan Reginald is currently the co-founder and the Chief Executive Officer of Celixir, which was founded by him in 2009 with Nobel Laureate Professor Sir Martin Evans. The original name of the company at the time of foundation was Cell therapy Limited.

Celixir is a private British regenerative medicine company that discovers and develops life-saving and life-altering regenerative medicines for patient’s cell and gene therapies for patients with the greatest medical need. Celixir’s unique rational design approach drives in-house discovery and has created a broad pipeline of cell and gene therapy medicines, with seven of these currently being taken forward through the development cycle.

At Celixir the pipeline is led by their investigational cardiac tissue engineered, cell therapy product, HeartcelTM which was designed keeping in mind to treat patients with heart failure undergoing coronary artery bypass graft (CABG) These HeartcelTM   are injected during the bypass surgery surrounding the cardiac scar tissue in one single application. Another one of Celixir’s products is in late-stage clinical development called TendoncelTM, It is for tendon repair and is currently being tested in patients who suffer from tennis elbow. In its clinical stage pipeline, Celixir is also progressing three oncology products and two further cardiac products through the pre-IND stage..

Ajan Reginald before starting on with the entrepreneurial mode has served as the Global Head of Emerging Technologies and Business Development Director at Roche Pharma where he has overseen the identification, acquisition and development of the next generation of quantum leap of biopharma technologies and products. He joined Roche as a Business Development Director where he completed over 30 M&A and licensing transactions including a $1.3B licensing transaction with Alnylam.

Before joining Roche, Ajan Reginald worked with the Boston Consulting Group (BCG) in the USA & Zurich as a member of both the Life Sciences Practice Area and Intellectual Property Group.  Ajan Reginald was formerly a dental surgeon but he had to retire after getting injured during a hockey match which resulted in a visual impairment.

Ajan Reginald is a Fulbright Scholar, graduate of the London Hospital School of Medicine and Dentistry (University of London) and holds an MBA from the Kellogg Business School at Northwestern University and an MSc in Experimental Therapeutics from Oxford University. He has also completed the Harvard Business School Advanced Management Program.

[celixirltd-blog]

Celixir LTD - Formerly Known as Cell Therapy Ltd

Celixir (formerly known as Cell Therapy Ltd.) is a private British regenerative medicine company that discovers and develops life-saving and life-altering regenerative medicines for patients with the greatest medical need.

Celixir, founded in 2009, is made up of a world-class team of scientists and biopharmaceutical executives, led by Nobel Laureate Professor Sir Martin Evans and former Roche Global Head of Emerging Technologies, Ajan Reginald.

Celixir’s unique platform technology allows us to adopt an ‘off-the-shelf’ approach to deliver regenerative medicines to patients. Website : http://www.celixir.com Headquarters : Cardiff, Wales Year Founded : 2009 Company Type : Privately Held Size : 11-50 employees Specialties : regenerative medicine, cell therapies, cardiovascular medicine, cellular research

[prabhudayalseo-blog]

How to Pursue a Career in Regenerative Medicine

Professor Sir Martin Evans, Celixir’s President, Chief Scientific Officer and co-founder, attended Christ’s College (a constituent college of the University of Cambridge) where he studied zoology, botany, chemistry and biochemistry. After graduating with a BA, he moved to University College London where he worked as a research assistant and graduated with a PhD. Not only did Sir Martin Evans isolate the first embryonic stem cells, he’s also published over 120 scientific papers and is the recipient of a Nobel Prize.

Celixir’s Chief Executive Officer and other co-founder, Ajan Reginald, whose background is in both science and business. Ajan holds four degrees and is an alumni of Harvard Business School, University of Oxford, Kellogg Business School and University of London. After serving as the Global Head of Emerging Technologies for Roche Group Research, he moved on to the Business Development Director at Roche Pharma. Since, he’s helped develop Celixir’s breakthrough technologies including Heartcel and Tendoncel.

[jordenredsald-blog]

Ajan Reginald is a hugely accomplished and widely recognized expert in the fields of Science and Medicine.

[ajanreginald]

Ajan Reginald: The regenerative medicine entrepreneur treating heart disease with stem cells

Ajan Reginald: The regenerative medicine entrepreneur treating heart disease with stem cells

Cardiovascular disease (CVD),  in all of its forms, is the number one killer in the UK, Europe and the US. More often than not, it has long-term effects, including an enlarged, damaged and less efficient heart muscle which naturally leads to other disabilities and a notably decreased quality of life.

While the affected person certainly bears the burden of such diseases, society as a whole does as…

[michellelewis7162]

Celixir- One Of The Best Cell Therapy Ltd Companies

Celixir- One Of The Best Cell Therapy Ltd Companies

Cell treatment or Cellular therapy (CT) is well-liked out there as a result of its own best functions. This is the one aids in hair transplant of individual tissues to change or restore ruined cells and/or tissues, help make one's life far better as well as long. Along with brand-new technologies, cutting-edge items, as well as endless creative imagination, currently our team may conveniently view several sorts of cells may be made use of as component of a treatment or therapy for a variety of conditions and also ailments. Celixir

There are great deals of cells that might be actually utilized for blood-forming stem cells (HSC), muscle stem tissues, mesenchymal stem tissues, and also several others have actually strengthened the life of all. Celixir is among the absolute best Cell Therapy Ltd firm that discovers and also builds life-saving and life-altering regenerative medications for clients along with the best health care necessity. There are lots of patients are actually losing their lives as a result of no good medicines, and the company is listed here to produce one thing the most ideal to heal all type of issues to offer people great as well as extended life.

Celixir was established in 2009, as well as currently possesses an excellent crew of the experts who basically associated with investigating and also explore things to generate the most effective remedy. They are actually operating in various outstanding traits are going to surely conserve folks from different conditions and also for that they won't need to spend considerably. The business has actually obtained an unparalleled staff of experts and also biopharmaceutical execs who are actually quite knowledgeable and also quickly will certainly give terrific solutions to the world. The firm is actually led by so expert and Nobel Laureate Professor Sir Martin Evans as well as past Roche Global Head of Emerging Technologies, Ajan Reginald made Celixir an extremely special system. This is actually the business recognized for improved innovation allows us to take on an 'off-the-shelf' strategy to supply cultural medications to patients.

Check Complete Details About Regenerative Medicine Company Celixir

Are you finding for the very best biotechnology and regenerative medicine company for better understanding and also various other objectives? There are actually bunches of companies are actually linked with the regenerative medicine, yet some are extremely different and received excellent appeal.

One such company coming from Stratford-upon-Avon is Celixir, really well-known as a result of its supreme and incredible innovations as well as tissue treatment which are FDA approved. The firm is actually all regarding to produce the most ideal answers to make sure that they could be resolved various wellness problems. The study and analysis is actually performed to generate the very best cultural medications and also various other solutions can help in bring back body organ feature, improve premium as well as duration of lifestyle and minimize healthcare costs as well as soon the business will quickly accomplish the exact same.

You should know that regenerative medication uses substantial capacity and option to help in unmet scientific as well as patient requirements which will definitely have a primary impact on scientific results as well as health care financial resources in the coming years with the aid of the staff of Celixir. This is actually the business, which is actually in the past referred to as Cell Therapy Ltd. is a personal British regenerative medication business that finds and creates life-saving and life-altering regenerative medicines. Quickly their advancement will help the patients with the biggest medical demand and they will certainly be happy along with the advancement is going to form their life soon. Celixir, started in 2009, as well as led by the Nobel Laureate Professor Sir Martin Evans and previous Roche Global Head of Emerging Technologies, Ajan Reginald, who are actually amazing in their work.

Celixir prospers and has a thus fantastic outstanding staff of researchers as well as biopharmaceutical execs will make it possible for folks to adopt an 'off-the-shelf' approach to provide regenerative medicines to people. The experts are actually regularly operating on generating and various other remedies for cultural medicine, cell therapies, cardio medication, cell investigation and additional to help people as well as to safeguard them from dangerous conditions.

Celixir-- The Best British Regenerative Medicine Company

When we talk regarding Regenerative Medicine, there is actually nothing at all much better than the same to aid us in enhancing the top quality of life as properly as creating our life sizable. With help from the same it is actually achievable to boost the high quality of life for people around the globe as well as everybody lags the exact same.

Referring to the really popular and also award-winning British cultural medicine provider Celixir is listed here to aid the medicine sector and the medical professionals with the most effective services which have not introduced however. The most ideal scientists' one can easily locate over there which are routinely working with this powerful technology to create brand-new body drop a person's own cells as well as cells along with they have various other programs to aid patients along with their A-Z demands. The moment one will definitely obtain the excellence, everything will definitely get eliminated, featuring the concept of cells turndown.

Celixir is definitely among the most ideal as well as popular firm, which is actually in the past called Cell Therapy Ltd. This is a personal British cultural medication provider that assists in finding out and also cultivating life-saving as well as life-altering cultural medicines for the clients with the biggest clinical necessity. The business has got the very best group of the professionals, who belong to the fields for several years as well as carrying out the most ideal for brining the distinct as well as excellent options. The crew of outstanding experts and medical management all are dedicated to discovering innovation medications that change the life of the clients.

The provider is effectively running by the pros along with the Sir Martin Evans, Nobel Laureate, as well as Ajan Reginald, previous Global Head of Emerging Technologies at Roche, originally established the provider under the title Cell Therapy Ltd (CTL) in 2009. Also, the firm- CTL was rebranded as Celixir in 2016 as well as got great attraction in the international market.

[ajanrginaldsc]

Future of Healthcare, AI, Blockchain, Mankind Interview Ajan Reginald Founder Celixir

Ajan Reginald is on a mission to reinvent healthcare, AI, cell therapy and in many ways the way the future of what human body will be and our singularity.

In this long (over 40 minutes) but very exciting interview, we spoke with Ajan Reginald, the charismatic Founder and thought leader behind Celixir, a company co-founded with Professor Sir Martin Evans, Nobel of Medicine. Indeed, in 1981, Sir Evans isolated the first embryonic stem cell and in 2007, his ground-breaking research awarded him with the Nobel Prize.

This interview highlights Ajan’s personal history and as well as several aspects of how his venture, Celixir, is working in breath through general trends developing cellular medicines to combat life threatening and life altering diseases.

Ajan also discusses general challenges and opportunities for life sciences and the healthcare industry such as AI, blockchain and related topics while focusing on the future of mankind with singularity.

Cell therapy

 Ajan Reginald

is the Executive Director of Celixir, a leading scientific company that develops cellular medicines and solutions to combat life threatening and life altering diseases. He is an Ex-Global Head of Emerging Technologies and Ex-Business Development Director at Roche.

Previously, he was a Consultant for the Boston Consulting Group. He studied at the Kellogg School of Management, was a Fulbright Scholar and did his initial academic studies at the University of London.

Ajan Reginald is a dynamic, hugely accomplished and widely recognised expert in the fields of Science and Medicine. His company, Celixir, quickly became an award-winning biotech company developing stem cell therapeutics with products already reaching phase II and phase III of clinical trials.

Celixir

Celixir develops a wide range of cell therapies but the company is currently focused on CVS indications: Heart Failure and Myocardial Infarction.

Prior to this, during his time at Roche, Ajan had already worked with cell therapies as he led efforts to identify and commercialise the best breakthrough life science technologies including a focus on stem cells.

During his career, Ajan has completed over 30 licensing and acquisition transactions as Business Development Director at Roche. He has a very solid background in life sciences combined with a business approach: From 2003 to 2005, when Ajan worked with the Boston Consulting Group in the USA and Zurich, he was a member of both the Life Sciences Practice Area and Intellectual Property Group.

Ajan is also a graduate of London Hospital School of Medicine and Dentistry and holds an MBA from the Kellogg Business School at Northwestern University.

Mr. Reginal enjoys spending time with his wife and young son and in his spare time he plays competitive Hockey, representing England at the over 40’s level.

His experience at Roche and BCG made him realise that when it comes to biotechnologies, only true breakthrough innovation is of value. That is what led him to focus and position his company.

As he says: “Innovation must be directly convertible into a benefit for the patient. You can only get rewarded as a company if you do something that is fantastically good for patients.”

Ajan has been working closely with Professor Sir Martin Evans,

his co-founder at Celixir. In 1981 Dr Evans isolated the first embryonic stem cells. Over his career Sir Martin Evans has published more than 120 scientific papers and received numerous awards for his ground-breaking research.

Alongside his 2007 Nobel Prize, Sir Martin has also been awarded the prestigious Albert Lasker Award in 2001, the Gold Medal of The Royal Society of Medicine, the Copley Medal of the Royal Society and the Baly Medal of Royal College of Physicians, all in 2009.

Ajan points out in the interview that despite the vast improvement in life expectancy over the last 200 years, “there is a large number of diseases that are still degenerative, chronic and ultimately fatal like heart disease.” Thus, Celixir approaches these incurable diseases with cellular therapies because normal medicines will not help. “In Western Europe, heart failure is the biggest cause of death, yet we don’t have anything that reduces the scar that is formed in the heart after a heart attack. We looked at that as a target. If this is something that can’t be cured by current medicines and evolution has given us this very interesting stem-cell-like technology, we should engineer the stem cell technology to produce a cellular therapy that can reduce scar in the heart.”

Does it work?

Ajan has a very clear response to their initial hypothesis: “We were beautifully lucky since this medicine seems to have a profound effect in reducing scar in patients. It is the first time it has been seen in humans. These are patients that within 10 years would have died of late stage heart failure.”

At Celixir, Ajan and his team mainly focus on cell therapies. He explains the difference between this approach and regular medicine:

“Disease happens at a cellular level. When we take an aspirin, often what we do is we are treating the symptoms, we are not treating the underline cell that had been damaged.Our cellular medicines have a totally different focus. Those medicines are aiming to restore and repair the damaged cells. It has a profoundly different impact.

[casuallyjollymoon-blog]

Ajan Reginald is the co-founder of Cell Therapy LTD, Ajan specialises in the research and development of new stem cell therapies and treatments as part of regenerative medicine.

[myjimmy76-blog]

Ajan Reginald is the co-founder of Cell Therapy LTD, Ajan specialises in the research and development of new stem cell therapies and treatments.   Celixir is a British biotechnology company that discovers and develops life-saving and life-altering regenerative medicines for patients with the greatest medical need.

[ajanreginalduk-blog]

How stem cell therapy is winning the medical world by its achievements?

Ajan Reginald comes as one of the co-founders of their firm Celixir, along with Professor Sir martin Evans. Ajan has earlier served as the global head of the emerging technologies and business development director at Roche. He has also served as the consultant at the Boston consultant group whilst being a bright scholar with an MSc in experimental therapeutics. He was recently been interviewed by one of the major online dailies and we present you with the excerpts of the same.

Phacilitate: Why does Celixir follow a non-traditional financing model?

Ajan Reginald:  It’s driven by two things, I think: first of all, we are in a new cutting-edge area, i.e. regenerative medicine. The second thing is that we’re a very British company; we’re British investors, based in the UK and funded in the UK.  

We, the founders, have put in a significant amount of the capital so far to get the company all the way to completing phase II trials. That’s quite unusual and I think that says a lot about our understanding and belief in the technology, and how we think it will be a paradigm-shifting technology. That might be based on the fact that we’re a little bit older and we’ve done a fair amount of time in biotech and pharma.

On the second point, the VC environment in Europe is a bit different to the US. There are some excellent VCs in Europe and there are some excellent VCs in the US; I just think the US has a larger number of VCs that have followed biotech, have done biotech deals, and who are therefore used to the high degree of uncertainty and volatility in biotech both from a technology perspective but also from a market perspective - so I think in Europe, the drivers to be more non-traditional are perhaps more apparent than in the US.

 Phacilitate: In terms of the financing environment in Europe, many European biotechs consider the US to be much healthier in this regard; does this tally with your own experiences?  What trends do you see developing in European private sector funding?

Ajan Reginald:  In the US, you’ve seen better valuations for platform technology companies and for earlier-stage companies. I think Circassia last year is a great example of a company that has a platform technology having a very successful IPO in Europe, in London, so I do think that trend is changing.

Our own experience, which is relatively recent – we’re doing a large private funding now – has been pretty similar. We picked 20 of the top European institutions and 20 of the top US institutions, and our hit rate is about the same at both.

I think in that top tier of the very sophisticated funders in Europe and the US, they’re just top people; they understand it. It’s not necessarily that they’re going to invest in you, but they definitely understand what they’re doing and how quickly they understand it is pretty much the same.

 Phacilitate: Did you consider Horizon 2020 as a potential financing source? What factors influenced your decision on whether or not to pursue this route?

Ajan Reginald:  Yes, we did consider Horizon 2020. I think the key driver there is the specificity of the call from Horizon 2020. If Horizon 2020 has a call that really fits what you’re doing as a company anyway and you have some good European collaborators, I think it’s an excellent programme.

I think the secret to this, which is the same for this grant as it is with any other, is make sure that what you’re doing as a company is critical to you and then look for a grant that fits, not the other way round – don’t try to manufacture a project to fit a particular grant.

 Phacilitate: Wales is becoming a force in the regenerative medicine space. What particular elements make it the ideal location for Celixir?

Ajan Reginald:  For us, we’ve been in Wales from conception, so hopefully we’re the spark for some of that. Very simply, for us it’s where our scientific founder, Sir Martin Evans, was based; it’s where he won his Nobel Prize, it’s where we have a lab, it’s where we have fantastically skilled scientists and where we’ve had significant support from the Welsh Government. I think the Welsh Government for us has been a very strong supporter, they are committed to developing an innovation-based economy and I congratulate them on that.

Phacilitate: Tell us about Celixir's priorities for the remainder of 2015 and beyond, particularly for the lead product, Heartcel.

Ajan Reginald:  2015 is going to be a big year. We are focused on Heartcel, but we also have completed phase II for our second product, Tendoncel, and the results for that were presented in June at the International Society of Stem Cell Research. Then also Skincel, our third product, is probably going to report in Q4, so 2015 is a busy year.

For Heartcel, we are interacting with the regulators currently. We’re looking to get orphan designation in place for Heartcel in Europe and we may then also apply for some of the US regulatory pathways as well. So yes, it’s going to be hopefully a very positive year in terms of our interactions with the regulators.

[celixirltd-blog]

Celixir announces US FDA approval of the IND application for cell therapy Heartcel

Celixir announces US FDA approval of the IND application for cell therapy Heartcel

FDA IND and UK MHRA CTA approval both achieved     in H1 2018

Potentially pivotal heart failure trial of up     to 250 patients in the UK and US

Celixir – Celixir, a privately owned company discovering and developing life-saving advanced therapies, announces that the US Food and Drug Administration (FDA) has approved its Investigational New Drug application (IND) for Heartcel its immuno-modulatory progenitor (iMP) cell therapy for the treatment of adult heart failure.

Celixir announced in January the approval of a clinical trial application (CTA) from the UK’s Medicines and Healthcare products Regulatory Agency to initiate a potentially pivotal Phase II b human clinical trial with Heartcel The international trial will recruit up to 250 patients and the IND approval allows expansion to US clinical trial sites.

Ajan Reginald, Chief Executive Officer of Celixir, commented: “The FDA approval of our IND is a significant regulatory milestone, which follows UK clinical trial approval in January. Celixir is now well positioned to conduct potentially pivotal trials with Heartcel™ in Europe and the US.”

About Celixir Celixir is a privately owned UK biotechnology company that discovers and develops life-saving and life-altering advanced therapies for patients with the greatest medical need. Celixir, founded in 2009, is made up of a world class team of scientists and biopharmaceutical executives, led by Nobel Laureate Professor Sir Martin Evans and former Roche Global Head of Emerging Technologies, Ajan Reginald. Celixir’s unique platform technology allows it to adopt an ‘off-the-shelf’ approach to deliver cell therapies to patients.

About Heartcel Heartcel is an allogeneic celixir cell therapy containing off-the-shelf immunomodulatory progenitor (iMP) cells engineered to regenerate the heart. Imps are administered during coronary artery bypass graft (CABG) surgery by direct injection around the cardiac scar that is to be regenerated. iMP cells have been designated an Advanced Therapeutic Medicinal Product (ATMP) by the European Medicines Agency. 

EU Phase II trials were successfully completed with results presented in 2016 at the congresses of the European Society of Cardiovascular and Endovascular Surgery and the European Society of Gene and Cell Therapy. All primary and secondary endpoints were met: 100% major adverse cardiac event (MACE) free survival; 30% improvement in heart function; 40% reduction in scar size; and 50% improvements in quality of life. In 2017, four-year follow-up analyses found the MACE-free survival rate remains at 100%. Potentially pivotal trials are approved to begin following US IND and UK CTA approvals. 

[nuttyhologramgoatee-blog]

5 Things We Know About the Potential of Stem Cells in Dentistry

Can you imagine a day where instead of having a filing, root canal, or dentures, you could regenerate your tooth? It is beginning to look like this will be a reality in the not too distant future, with the help of stem cells. The potential of regenerative medicine in dentistry has been well documented over recent years, for a number of key reasons. As more research takes place we take a look at what we know already. Teeth are the most natural and non invasive source of stem cells.

Stem cells in teeth are the most easily accessed in all the body, requiring no surgical procedure to remove them, and therefore no discomfort to the patient.

Stem cells extracted from dental pulp are the best preserved

Dental stem cells have been found to be better preserved than stem cells from other areas of the body. They also replicate at a faster rate, and for a longer period of time than those found in other parts of the body.

You could use patients own cryopreserved pulpal stem cells

By harvesting stem cells from your own healthy teeth earlier in life, and then cryopreserving them, you stand the best chance of having the best stem cells for future regeneration of your dental or alveolar tissue.

These could be taken at routine dental visits from teeth that are cavity and infection free. The best candidates are wisdom teeth of 18-20 year olds because of the large pulp size.

You can repair and regenerate lost structures of the tooth Whilst current therapeutic interventions in dentistry aim to prevent further destruction of the tooth, this breakthrough would allow reconstruction and re-growth of the destroyed tooth. This would be particularly helpful for those suffering with advanced periodontitis where the natural architecture of the tooth could be restored and the condition reversed. There is the potential to regenerate a whole tooth Embryonic tooth-germ transplantation into alveolar bone in animal models has already been successful. Using stem cells and a ‘scaffold’, which mimics the three-dimensional structure of tooth buds as they form, scientists have already succeeded in whole tooth regeneration in a pig’s jaw. This opens up potential for a progressive new way to treat tooth loss in the future. Ajan Reginald, co-founder of Cell Therapy Ctd, and ex Global Head of Emerging Technologies at Roche, believes that this could be a rapidly growing area in regenerative medicine.

For more information about Stem Cells please visit the website

[celixirltd-blog]

Celixir’s CEO discuss about his agreement with the Japanese firm to distribute its heart failure drug

Just days after the Cardiff-based cell therapy company Cell Therapy Ltd (CTL) signed an agreement with Japan’s Daiichi Sankyo, providing them with the rights to its heart failure drug Heartcel, the company’s chief executive, Ajan Reginald, got interviewed by one of the leading dailies.

Heartcel, an immune-modulator progenitor (iMP), can be considered as one of the allogeneic celixir stem cell therapy which posses the power to redevelop the human heart. The same therapy has confirmed two-year MACE-free survival for all the tested patients in the Phase II clinical trial studying myocardial regeneration. 

As per the agreement, Daiichi Sankyo will take care of the development, regulatory approval and marketing of Heartcel in the Japanese territory, while CTL will still holds the rights for the rest of the world.

Mr. Ajan Reginald, the co-founder of CTL, quoted that the deals comes as a future step towards accomplishing the global mission of bringing company’s life-saving drugs to the world’s markets within a short period of time.

“Japan was a natural priority because it has an accelerated pathway that allows innovative regenerative medicines to reach patients much faster,” he said. “It is also very important commercially because it is the world’s second biggest pharmaceutical market.’

He also said that the company is ‘agnostic’ towards bringing these medicines to the global markets within a short period and they are open to all the available options in the same regards.

“Partnerships are a tool, but sometimes we are the best company to do it. It varies by territory. In Japan Daiichi Sankyo was identified as the best partner”, he added.

It was October last year when CTL received the permission for the conditional marketing authorization for Heartcel in European region.

“There are multiple ways of bringing life-saving medicines to market, conditional approval is one way but there is also the Phase III route which is what we will do in the US,” he explains.

He also confirmed that CTL is currently looking for a partner in the US on Heartcel and various other discussions are in pipeline for a European partnership for its second asset named, Tendoncel.

This topical regenerative medicine which is quite helpful in treating certain severe tendon injury is geared up to enter its Phase III trials, after receiving positive results from Phase II.

Mr. Ajan Reginald also puts his stamp on the healthy financial state of the company. “It is a private company, still managed by the founders, so we have been prudent in our use of funds and also prudent in our fundraising. We were well-capitalized ahead of this partnership.” he said

 He further expects an initial public offering (IPO) to be coming out anytime around next year.

Ajan Reginald concluded the interview whilst saying, “I think we have a strategy which is to fund the company until the innovation and product revenues can drive sustainable development of our pipeline. We are not against an IPO but we won’t consider it until next year,”

[celixirltd-blog]

Global Partnerships Held by Celixir to Promote their Regenerative Medicines Worldwide

Celixir comes as a UK firm indulged in the discovery and development of life changing regenerative medicines and whilst working towards their common goals via collaborative partnerships. That said; let’s take a look at their collaborations with various recognized firms and institutions in the past few years.

DAIICHI SANKYO

Celixir has granted the Japan license for their innovative cardiac regeneration medicine to Daiichi Sankyo on May 2016. As per the agreement, Daiichi Sankyo will be taking care of all the development, regulatory and commercial activities regarding Celixir’s immunomodulatory progenitor cells within Japanese territory. On the other side, Celixir will be taking care of the worldwide rights for Celixir stem cells therapy for the rest of the world.

INNOVATIVE CARDIOVASCULAR MEDICINES COLLABORATION

Celixir has further formed the Innovative Cardiovascular Medicines Collaboration which includes global experts in cardiac research and clinical development, coming onboard with a common purpose of getting a basic understanding for cardiac regeneration.

This Collaboration will be headed jointly by Professor Kim Fox, Consultant Cardiologist and Professor of Cardiology at Imperial College and Professor Sir Martin Evans celixir, who is a Nobel Laureate along with the Chief Scientific Officer of Celixir.

The same collaboration will be supported by Professor John Pepper, OBE, Interim Director of Research at the Royal Brompton and Harefield NHS Foundation Trust, together with Dr. Sabena Sultan, Global Head of Research at Celixir stem cells office.

Talking about the same collaboration, Ajan Reginald, CEO, of Celixir cell therapy, said, “Collaborations with world-class research physicians are critical in accelerating the development of innovative medicines. We’re delighted to be forming this partnership with Professors Fox and Pepper, to advance Celixir’s investigational myocardial regeneration medicine and provide future innovations that will hopefully transform patients’ lives”,

The Collaboration was formed with the key priority of investigating heart failure whilst focusing on the progressive insights into the regeneration of cardiac tissue. Same collaboration would then think about bringing all the life-saving medicines to help and support millions of heart failure patients.

TMC LIFE SCIENCES AND THOMSON MEDICAL

Celixir cell therapy has also formed collaboration with TMC Life Sciences Bhd (TMCLS) and its flagship company, Thomson Medical (Thomson) to further trigger the discovery and development of life-changing and life-altering regenerative medicines. Going by the Memoranda of Understanding (MOU), Celixir will further be developing the educational programmes to successfully train all the medical professionals in regenerative medicine with their partner hospitals (TMCLS and Thomson). On the other side, TMCLS and Thomson will be providing an access to their pan-Asia development, clinical trials and hospital network.

[ajanreginalduk-blog]

Ajan Reginald A Recognized Hockey Player

Ajan Reginald, CEO and founder of Celixir, a stem cell research company holds its conception from the year 2006 when it was named Cell therapy ltd. The company was found by Ajan Reginald along with Nobel laureate Sir Martin Evans, it was later rebranded to Celixir in the year 2016.

 The company is working in the fields of research on another level. The company has recently launched two of its supreme products Heartcel and Tendoncel and successfully run their trials. These products are a feather on the advancements made in the field of science and technology. 

Ajan Reginald is one of the most successful entrepreneurs in the field of science and research and his extraordinary work can be seen in the form of his supreme products and results of research.

[ajanreginalduk-blog]

Ajan Reginald  A Cure for the Broken Heart ?

 Ajan Reginald As start-up ideas go, this has to be one of the best: Ajan Reginald wants to mend broken hearts.

Medically speaking, that is.

Heart disease affects about 30 million people globally, causes an estimated 4 million deaths per year in Europe, and is the primary cause of death in the developed world. Although modern medicines can provide a degree of relief, the harsh reality is that today there is no cure.

But there may be. Ajan (Chicago, Zurich, 2003-2005) is the founder and CEO of Cell Therapy Limited (CTL), a biotech firm he started in 2009 to experiment with stem cells as a way to fix damaged heart tissue.

“It was my dream to start a company that melds great science with great business to produce great benefits,” said Ajan.

It doesn’t hurt that his cofounder is Professor Sir Martin Evans, a Nobel laureate who first isolated and grew embryonic stem cells at Cambridge University back in the 1980s.

“Martin has a vast depth of understanding, expertise, and intuition, all of which are fantastic leadership qualities. But he also brings strong contributory assets that make him a brilliant person to start a company with,” said Ajan.

For the first six months, it was only the two of them. “We were a genuine start-up, doing everything ourselves: designing experiments, registering the company, raising funds, and setting up the website. We were certainly unique in that we had a Nobel Prize winner answering the phones.”

CTL has since identified a way to treat people with the most severely damaged hearts—those whose only hope is to receive a transplant.

“We’re treating people who have a life expectancy of less than one year—with 70 percent one-year mortality,” said Ajan.

And this is where the “great science” part of his dream comes in to play.

CTL’s proprietary cell therapy claims unique properties. “It’s a paradigm-shifting technology. Today’s medicines can only keep a patient from getting worse. We’re looking, for the first time, at a medicine that is able to regenerate a damaged organ.”

Heart failure develops after a person has a heart attack or when the arteries of a person’s heart are blocked. The heart muscle gets damaged and forms nonfunctioning scar tissue. Without treatment, this scar tissue expands, leading to heart failure and a significant chance of death within a few years.

CTL’s stem-cell therapy can be injected into scar tissue to reduce the size of the scar, stimulate repair, improve the heart’s ability to function, and mitigate the likelihood of heart failure.

Although there are other biotech firms working to produce stem cells for the broad treatment of diseases—using the same stem cell for, say, the treatment of lung disease or a chronic joint problem—CTL is unique in that it has been able to identify and isolate heart-specific stem cells.

The firm has already completed successful clinical trials, which brings us to Ajan’s vision of a “great business.”

The fast-growing high-tech stem-cell market is projected to reach about $20 billion in five years, and CTL hopes to tap into that market. Last year, in what was an unusual move for a biotech start-up, the firm ran an external fund-raising campaign that included crowdfunding; the goal was to raise £1 million. Ajan anticipated it would take up to three months to hit his target.

It took just ten days.

“The fact that we met our goal in such a short time shows that exceptional science for the benefit of society is an exciting investment proposition. This outcome is consistent with my BCG experience: clients with a focus first and foremost on quality produced highly differentiated products with demonstrable benefits, and profits followed. BCG gave me the analytical skills to understand these important drivers of great companies; hopefully I can replicate these characteristics in our small firm.”

In CTL’s case, demonstrating benefits demands a meticulousness in the way it generates value for heart patients. “Scrupulousness in value-generation for our patients translates into value-generation for our shareholders,” Ajan says.

In addition to Sir Martin Evans, CTL’s leadership team boasts other prominent figures, including Rhodri Morgan, a former first minister of Wales, Mubasher Sheikh, a former transplant surgeon and the current head of Permira health care, and Lord Digby Jones, a former UK minister of state for trade and development.

“It’s important to surround yourself with smart, critical people and to listen to them. Again, this is something I learned at BCG. I’m fortunate to have an exceptional board and executive team, and I am careful to listen, but ultimately I’m responsible for the decisions, good or bad. And I’m happy to make those calls.”

Ajan likens his role among these iconoclasts to his position as a central midfielder in field hockey. (He currently represents the England Masters at the international level.) “In other words,” he says, “I’m expected to see everything, anticipate everything, and cover every inch of the pitch. I’ve got to be a total team player—attacking, defending, and fulfilling whatever role is required by the team.”

“CTL is like most biotech companies in that it requires a CEO to understand and connect the science with the biotech business,” says Ajan. “However, where CTL may be different is the dual-fold novelty and ambiguity of both our field of regenerative medicine and CTL’s unique approach. The novel approach in an unproven field and being at the fore-front. There is no path to follow. Therefore, we believe an in-depth level of science and business expertise is necessary to make these critical (and novel) decisions.

“BCG was the best preparation for this role. I found my BCG experience very challenging and the hardest job I’ve ever done. But in hindsight, it was great training. The intellectual capacity needed, the speed of thought and execution required, and the unrelenting pressure and ‘stretch’ is how I developed my capacity to perform critical operations under high stress. BCG trained me to think and to work in a high-performance team. I learned to be data driven and to recognize excellent analysis and the singular value of insight from that analysis. Ultimately, leaving BCG was right for me. But the hard-won BCG skills gave me the ultimate confidence to use data to make the most critical decisions.

“My experiences from high-performance sports teams and BCG are complementary. High-level hockey is fast and dynamic; tactical thinking on the fly is very hard. But for me, the single well-executed tactical decision that wins the game is compelling. In contrast, business is more strategic and tactical, and there’s more time to think. However, it’s much more difficult to produce ‘game winners’ in business, and it’s much harder to build a high-performance team. That may be because the time frames are longer, prolonged years of rigor are required, and the rewards are less connected with actions.

“When we started CTL, we decided to combine the teamwork of high-performance sports with the strategy and execution required to excel in business. Therefore, our team is nontraditional—perhaps to match our nontraditional scientific approach.

All of which, he says, is borne out in the success of CTL.

“If your high-performance team can work synergistically, excellence is a more likely outcome—be it at BCG, international hockey, or a biotech firm. I truly believe there are few limitations on the productivity of such organizations. You also need luck, however, and then you just might develop the world’s first regenerative medicine.”

CTL, which is based in Cardiff in the UK, now has 30 employees, holds more than 100 patents, and is affiliated with labs at leading universities in Oxford, Toronto, Denmark, Greece, and China.

“Our goal is to treat 100,000 critically ill patients within the next five years,” Ajan concluded. “Realizing the great responsibility of lifesaving medicines, we focus on bringing Heartcel to market rapidly. It’s an amazing time—simultaneously frightening, humbling, and awe-inspiring.”